A recent study shows a 4-week dietary intervention can reduce biological age by 2-3 years using the KDM clock. Experts discuss implications for metabolic health and aging. New research suggests that s...
New research shows modifiable lifestyle factors add up to 7 years of life expectancy in older adults, even those with high genetic risk. A landmark study reveals that diet, exercise, and not smoking c...
The 2025 longevity investment landscape shifts from narrow anti-aging to a full innovation stack, led by cellular reprogramming, brain longevity diagnostics, and platform infrastructure. Investors pou...
Senolytics like dasatinib and quercetin are transforming dermatology from cosmetic fixes to true biological rejuvenation, with recent trials showing improved skin elasticity and potential for treating...
Phase 1 data for BGE-102 demonstrates significant reductions in hsCRP and inflammatory biomarkers, positioning it as a potential best-in-class therapy for cardiovascular risk and age-related inflammat...
ER-100 targets glaucoma and NAION through epigenetic reprogramming, with Phase II trials advancing, highlighting potential economic and healthcare disruptions in anti-aging therapies. Life Biosciences...
Life Biosciences launches a Phase I trial for cellular reprogramming to treat age-related macular degeneration, challenging aging norms with FDA’s Plausible Mechanism Pathway, amid rising invest...
Recent research reveals how mitochondrial decline accelerates cellular senescence in blood vessels, driving conditions like atherosclerosis and blood-brain barrier leakage, with emerging therapies tar...
Recent breakthroughs in senolytic and senomorphic therapies, including polyunsaturated lipids inducing ferroptosis, are advancing clinical trials for age-related diseases, with a focus on safety and b...
Recent studies show Roseburia inulinivorans boosts muscle strength in aging, with probiotics targeting sarcopenia gaining traction in the wellness market amid regulatory and ethical debates. Breakthro...
